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The XPC gene is involved in repair of bulky DNA adducts formed
by carcinogenic metabolites and oxidative DNA damage, both
known bladder cancer risk factors. Single nucleotide polymor-
phisms (SNPs) in XPC have been associated with increased blad-
der cancer risk. Recently, rarer genetic variants have been
identified but it is difficult to ascertain which are of functional
importance. During a mutation screen of XPC in DNA from
33 bladder tumour samples and matched blood samples, we iden-
tified five novel variants in the patients’ germ line DNA. In a case–
control study of 771 bladder cancer cases and 800 controls,
c.905T>C (Phe302Ser), c.1177C>T (Arg393Trp), c.156G>A [3#
untranslated region (UTR)] and c.2251-37C>A (in an intronic
C>G SNP site) were found to be rare variants, with a combined
odds ratio of 3.1 (95% confidence interval 1.0–9.8, P 5 0.048) for
carriage of one variant. The fifth variant was a 2% minor allele
frequency SNP not associated with bladder cancer. The two non-
synonymous coding variants were predicted to have functional
effects using analytical algorithms; a reduced recruitment of
GFP-tagged XPC plasmids containing either c.905T>C or
c.1177C>T to sites of 408 nm wavelength laser-induced oxidative
DNA damage was found in vitro. c.156G>A appeared to be as-
sociated with reduced messenger RNA stability in an in vitro
plasmid-based assay. Although the laser microbeam assay is rel-
evant to a range of DNA repair genes, our 3# UTR assay based on
Green fluorescent protein(GFP) has widespread applicability and
could be used to assess any gene. These assays may be useful in
determining which rare variants are functional, prior to large
genotyping efforts.
Introduction
Transitional cell carcinoma of the bladder is the fourth most common
cancer in Western men (1) with cigarette smoking and exposure to
industrial chemicals being major risk factors. Carcinogen metabolism
generates bulky DNA adducts, repaired by nucleotide excision repair
(NER), which also repairs some endogenously generated oxidative
DNA lesions (2).
Xeroderma pigmentosum (XP), a rare autosomal recessive disorder
characterized by a high incidence of skin cancer, involves mutations
in NER genes (3,4). One such gene, XPC, on chromosome 3p25,
encodes a protein forming a heterotrimeric complex with RAD23B
and centrin 2 (4,5), which recognizes and binds to helix-distorting
DNA adducts (6). XP-C patients have a 1000-fold increased incidence
of skin tumours but, as few patients survive beyond early adulthood,
internal malignancies have only rarely been reported (7). The esti-
mated 1 in 500 individuals heterozygous for an XPC mutation are also
at increased risk of malignancy (8), as reported for heterozygous
mutations in other recessive DNA repair disease genes (9,10).
XPC knockout mice have an increased risk of skin tumours follow-
ing ultraviolet (UV) B radiation, and also develop liver and lung
tumours following exposure to the chemical carcinogen acetylamino-
fluorene (11) reflecting defective NER. They have a 100% incidence
of spontaneous lung tumours (12,13), attributed to defective repair of
endogenous oxidative lesions. It is now clear that the XPC protein is
involved in repair of oxidative DNA lesions not only via its NER
function, repairing bulky oxidative lesions including 8,5#-cyclopurine
2#-deoxynucleosides (14,15), but also through XPC-RAD23B acting
as a cofactor both in the base excision repair of 8-hydroxyguanine, by
stimulating OGG1 activity (15), and in base excision repair of T/G
mismatches, by stimulating thymine DNA glycosylase activity (16).
During a mutation screen of XPC in DNAs extracted from 33 bladder
tumours, we found five previously unidentified XPC variants in both
tumour and matched germ line blood DNAs. We performed a case–
control study, and one variant (c.621 þ 22G.A) was revealed as
a 2% minor allele frequency single nucleotide polymorphism (SNP)
not associated with bladder cancer risk. The remaining four variants,
namely c.905T.C (rs121965091), c.1177C.T (rs1211965090),
c.156G.A (rs121965092) and c.2251-37C.A (rs2470353), were rare
in the case–control analysis. As we hypothesized that the rare coding
and 3# untranslated regions (UTR) variants might have a functional
impact, we assessed their effects on XPC protein recruitment to focal
DNA damage and on messenger RNA (mRNA) stability.
Materials and methods
Study population and clinical materials
Local ethical approval was granted by the Leeds Teaching Hospitals Local
Research Ethics Committee and informed consent obtained. DNA from 33
fresh-frozen bladder transitional cell carcinomas (16 pTaG2/G3, 10 pT1 at least
G2/G3, six pT2 at least G3 and one pTxG3) was extracted using a QIAamp DNA
Micro kit (Qiagen, Crawley, UK), and DNA extracted from 32 matched bloods
(one tumour having no available matched blood) using the Puregene modified
salt precipitation method (Flowgen, Nottingham, UK). The case–control study
population has been described previously (17).
Cell lines
RT112M bladder cancer cells were grown at 37C in a 5% CO2 humidified
atmosphere, cultured in RPMI 1640, 10% fetal bovine serum, 1% L-glutamine
and passaged for fewer than 6 months. This cell line has been authenticated in
the MK laboratory by extensive genomic analysis (microsatellite typing, con-
ventional karyotypic analysis, MFISH and array-based copy number analysis).
Mutation detection
All 16 exons and the 5# and 3# UTR of the XPC gene were amplified from
tumour DNA by polymerase chain reaction (PCR) (supplementary Table I is
Abbreviations: cDNA, complementary DNA; CI, confidence interval;
DHPLC, denaturing high-performance liquid chromatography; mRNA, mes-
senger RNA; NER, nucleotide excision repair; OR, odds ratio; PCR, polymer-
ase chain reaction; SNP, single nucleotide polymorphism; UTR, untranslated
region; UV, ultraviolet; XP, xeroderma pigmentosum.
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available at Carcinogenesis Online). PCR reactions were carried out in a total
volume of 20 ll containing 20 ng DNA, 0.5 U Thermostat (Abgene, Epsom,
UK), 2 ll of manufacturer’s buffer, 0.5 mM forward and reverse primers,
10 mM deoxynucleoside triphosphates, 3 mM MgCl2 and 5% dimethyl sulf-
oxide, on a PTC200 DNA engine (GRI, Braintree, UK). Thermal cycling
parameters were: 95C for 12 min, 35 cycles of 95C for 30 s, optimal primer
annealing temperature for 30 s, 72C for 30 s, followed by a final extension of
72C for 10 min.
Ten microlitres of PCR products were denatured at 95C for 5 min and allowed
to cool to 65C for the formation of heteroduplexes. Denaturing high-perfor-
mance liquid chromatography (DHPLC) was carried out using a Transgenomic
WAVE Nucleic Acid Fragment Analysis system and DNASep column (Trans-
genomic Ltd, Glasgow, UK). The composition of buffer A was 0.1 M trimethy-
lammonium acetate; buffer B contained 0.1 M trimethylammonium acetate and
25% acetonitrile. Analysis was carried out at a flow rate of 0.9 ml/min1 and
a buffer B gradient increase of 2%/min1 for 4 min. Start and end concentrations
of buffer B were determined empirically for each fragment. If the results were
not conclusive, then the DHPLC was conducted at two temperatures. DHPLC
data analysis was by visual inspection of sample and reference chromatograms,
with results scored independently by two researchers.
Sequencing in bladder tumours
PCR reactions were carried out in a total volume of 20 ll containing 20 ng of
DNA, 10 ll HotstarTaq Master Mix (Qiagen), 0.5 lM forward and reverse
primers (supplementary Table I is available at Carcinogenesis Online). Ther-
mal cycling parameters were 15 min at 95C, followed by 45 cycles of 95C for
30 s, optimal primer annealing temperature for 30 s and 72C for 30 s, followed
by a final extension of 72C for 10 min. The PCR products (5 ll) were treated
with 1 ll of exonuclease I and 2 ll of Shrimp alkaline phosphatase (USB
Corporation, Cleveland, Ohio) at 37C for 30 min to remove unincorporated
nucleotides followed by heat inactivation at 80C for 15 min. Three microlitre
of treated PCR products were forward and reverse sequenced using HalfBD
with the ABI BigDye Terminator reaction and analysed on a 31301 Genetic
Analyser (Applied Biosystems, Foster City, CA). Sequences were analysed
using the reference sequence, GenBank accession number AC090645.
Genotyping by Taqman and pyrosequencing
Variants c.621þ22 G.A, c.905T.C (rs121965091) and c.156 G.A
(rs121965092) were genotyped using the allelic discrimination 5# nuclease
assay (Taqman; supplementary Table II is available on Carcinogenesis Online),
as described previously (17,18), but with 50 cycles for c.621þ22 G.A.
Known-mutant DNA samples were included in a test run to help identify
clusters. Assays for c.1177 C.T (rs121965090) and c.2251-37C.A
(rs2470353) were designed using the Pyrosequencing Assay Design Software
(Biotage, Uppsala, Sweden and Qiagen): c.1177 C.T biotinylated forward
primer (5#TGCCAAAGGGAAGAGGAACA3#), reverse primer (5#GTCTCCTG-
GGCCCTCATCTT3#) and sequencing primer (5#TGGAGGAGGGCTTGC3#).
c.2251-37C.A biotinylated forward primer (5#GAGGTACACATTCC-
CAAACTCG3#), reverse primer (5#GAAGGTAAGGGCAGCATCAGA3#)
and sequencing primer (5#CAGGCCGCCTTGTTCC3#). PCR reactions were
carried out in 96-well plates on a PTC-225 Thermocycler (Bio-Rad Labora-
tories, Hercules, CA), using a total volume of 20 ll containing 20 ng of DNA,
10 ll of 2 Hotstar Taq Master Mix (Qiagen), and final concentrations of 0.2
lM each of forward and reverse primers, and 0.5 mM additional MgCl2.
Thermal cycling parameters were 15 min at 95C, followed by 35 cycles
of 30 s each at 94C, 63.4C and 72C, followed by 10 min at 72C. PCR
products were run on the Pyromark ID system (Biotage) according to the
manufacturer’s standard protocol. Five percent of samples were re-genotyped
with 100% concordance.
3#UTR plasmid reporter system and FACS analysis
Plasmid pTH-GFPa (19), a generous gift from Thomas Hughes, Leeds Institute
of Molecular Medicine, University of Leeds, UK, consists of GFP cloned into
pcDNA3MycHis (Invitrogen, Paisley, UK). The 5#- and 3#-UTR regions of XPC
were cloned into pTH-GFPa, flanking the GFP coding region and replacing the
plasmid viral 5#- and 3#-UTR regions to minimize extraneous DNA. The change
c.156G.Awas introduced into the 3#-UTR region by site-directed mutagenesis
(Quik Change Mutagenesis kit II; Stratagene, Stockport, UK), (Figure 1a).
RT112M bladder cancer cells were seeded into six-well plates (4  105
cells) and 24 h later transfected with pcDNA3MycHis and a GFP-containing
test plasmid (at 10:1 ratio to prevent saturation of the system with GFP) using
Fugene (1 l DNA: 3 ll transfection reagent). Following overnight incubation,
duplicate wells were analysed by Fluorescence activated cell sorting (FACS)
(LSRII and FACSDiva software; BD, Oxford, UK) using mean fluorescence
intensity to determine GFP protein expression levels.
RNA was isolated from the remaining two wells using a GenElute total
RNA kit (Sigma, Dorset, UK) as per the manufacturers’ protocol and used to
synthesize complementary DNA (cDNA) using random hexamers and M-MuLV
reverse transcriptase (New England Biolabs, Hitchin, UK). Quantitative real-
time reverse transcription–PCR was performed in triplicate using 1% of this
cDNA as template and SYBR green I as the fluorescent reporter. GFP mRNA
was quantified relative to expression of the constitutively expressed housekeep-
ing gene 36B4 (supplementary Table III is available on Carcinogenesis Online).
The Ct value was adjusted to account for differences in transfection efficiency
(number of GFP protein expressing cells as determined by FACS analysis,
doubling of mRNA for change in Ct value of 1). mRNA levels were normalized
to the wild-type mRNA expression using the DDCt method.
Preparation of XPC mutant plasmids and site-directed mutagenesis
Plasmid pLGR224-XPC-GFP was a generous gift Dr Jaime Angulo-Mora, Com-
missariat a` L’Energie Atomique, Fontenay aux Roses, France. This contained
a mutation c.1399C.A, coding Gln467Lys, predicted to be silent by SIFT (http://
sift.jcvi.org/), Polyphen (http://tux.embl-heidelberg.de/ramensky/), Pfam (http://
pfam.sanger.ac.uk) and NPS@ (http://pbil.ibcp.fr). However, this variant was
converted back to wild-type (c.1399C) using a QuikChange Multi Site-Directed
Mutagenesis Kit (Stratagene). Variants were then introduced using the same kit
(primer sequences available on request), and the changes in the DNA sequence
confirmed by direct sequencing.
Laser microbeam irradiation experiments
RT112M cells were seeded onto 35 mm glass-bottomed dishes (8  105 cells)
and 24 h later transfected with the pLGR224-XPC-GFP-based plasmids using
FuGene HD transfection reagent (2 lg DNA:6 ll Fugene; Roche, Burgess Hill,
UK). Twenty-four to 30 h posttransfection, the growth medium was replaced
with Optimem (Gibco, Paisley, UK), containing 10% fetal bovine serum. Live
cell imaging experiments were performed on a Nikon Eclipse TE2000E con-
focal laser scanning microscope system (60/1.4 objective) at 37C. Micro-
irradiation was carried out using a 17 mW 408 nm diode laser set to maximum
power. Cells with intermediate fluorescence levels were selected for treatment,
on the assumption that they would have similar protein expression levels. Cells
were focally damaged using the Zoom FRAP 2.1.848 macro (to detect fluo-
rescence recruitment after photodamage), with one laser pulse (duration 1.06 s)
to a nuclear spot 176 nm in diameter. Recruitment of fluorescent protein was
recorded using time-lapse microscopy with a calibrated 488 nm argon laser
(10% power to reduce photobleaching), with one pre-irradiation image and at
subsequent 5 s intervals for 4 min postirradiation. Five to ten G1 phase cells
were treated per experiment. All treated cells were analysed at the same mag-
nification with a zoom factor of 8, frame size 512 512 and pixel size 51.8 nm.
All images were processed using ImageJ software [see (20) for details] to
analyse the recruitment kinetics.
Statistical analysis
All statistical analyses were performed using Excel and SPSS software. Anal-
ysis of genotyping data was as described previously (18). Student’s t-test was
used for comparison of means. Pairwise correlations between the relative
Fig. 1 3# UTR plasmid reporter system and FACS analysis (n5 3, duplicate
wells analysed in each experiment, two-tailed t-test, error bars standard
deviation). (a) Schematic diagram of pTH-GFPa constructs used in mRNA
translational efficiency assays. (b) Mean fluorescence intensity of RT112 cells
transfected with GFP-flanked by mutant 3# UTR sequences relative to that of
GFP-flanked by wild-type XPC UTR sequences, and relative levels of GFP
mRNA analysed by quantitative reverse transcription–PCR using the DDCt.
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expressions levels were analysed by the Pearson correlation coefficient. Odds
ratios (OR) and 95% confidence intervals (CIs) were calculated from logistic
regression models to assess the effect of the three rare variants and the com-
bined effect of the three variants (1 rare allele versus no rare alleles) on
bladder cancer risk. P values , 0.05 were considered statistically significant.
For the combined genetic effect, assuming a binary variable (1 rare allele
versus no rare alleles) with a prevalence of 0.5% amongst controls, the power is
13% when the OR is 2.0 and 40% when the OR is 3.0.
Results
No XPC mutations found in bladder tumours
Internal malignancies have been reported in XP-C patients (7) and are
thought to arise from unrepaired oxidative damage resulting in TP53
mutations (21). As TP53 mutations are commonly seen in muscle
invasive bladder tumours (22), we looked for XPC mutations in 33
human sporadic bladder tumour specimens. At least one variant in
each of XPC exons 1, 2, 5.1, 7, 8, 10–15, the 3# UTR and flanking
regions was detected by DHPLC screening. The exact nature of each
variant was determined by direct sequencing of both tumour and
matched germ line DNA. No somatic mutations were identified in
the bladder tumour samples. However, in matched germ line DNA,
we identified 19 known SNPs. Comparison of tumour and germ line
DNA revealed allelic losses at 11 polymorphic sites (loss of hetero-
zygosity), in two muscle invasive tumours; this has also been de-
scribed in human lung and ovarian tumours (12,23).
Five novel XPC variants in germ line DNA from bladder cancer
patients
Five additional variants not annotated in dbSNP (www.ncbi.nlm.nih.
gov/projects/SNP/) were identified (supplementary Figure 1a is
Table I. Genotyping of the three rare variants
Variant Amino acid
substitution
Allele frequency
amongst controls
Genotype Controls (%) Cases (%) OR (95% CI)
c.2251-37 rs2470353 Triallelic:
C.G SNP, C.A rare variant
Intron 11 0 CC 201 (27.2) 183 (25.4) 1
CG 358 (48.4) 347 (48.1) 1.1 (0.8–1.4)
GG 181 (24.5) 190 (26.3) 1.2 (0.9–1.5)
CA 0 (0) 2 (0.28) ND
AA 0 (0) 0 (0) ND
c.1177C.T rs121965090 Arg393Trp 0.002 CC 790 (99.6) 750 (99.1) 1.0
CT 3 (0.4) 7 (0.9) 2.5 (0.6–9.5)
TT 0 (0) 0 (0) ND
c.905T.C rs121965091 Phe302Ser 0.0006 TT 787 (99.9) 757 (99.7) 1.0
TC 1 (0.1) 2 (0.3) 2.1 (0.2–23.0)
CC 0 (0) 0 (0) ND
c.156G.A rs121965092 3# UTR 0 GG 785 (100) 759 (99.9) 1.0
GA 0 (0) 1 (0.1) ND
AA 0 (0) 0 (0) ND
c.2251-37C.A, c.1177C.T
c.905T.C and c.156G.A combined
No rare allele 771 (99.5) 735 (98.4) 1.0
1 rare allele 4 (0.5) 12 (1.6) 3.1 (1.0–9.8)a
aStatistically significant with P-value , 0.05.
Table II. Haplotypes for the individuals carrying the rare variants
Case/control Age Smoking New rare variants SNPs associated with bladder cancer risk
c.2251-37 C.A
Intron 11 rs2470353
c.1177 C.T
Arg393Trp
rs121965090
c.905 T.C
Phe302Ser
rs121965091
c.156G.A 3#
UTR rs121965092
c.1496C.T
Ala499Val (rs2228000)
c.611 T.A, Ex15-184
(rs2470352) and
c.618 A.Ga, Ex15-177
(rs2470458)
Cases
1 86 48years wt het wt wt wt wt
2 82 16 years wt het wt wt wt wt
3 79 non-smoker bwt wt het wt het het
4 75 31 years wt het wt wt wt wt
5 76 40 years bwt wt wt het wt wt
6 63 4 years wt wt het wt wt wt
7 63 37 years wt het wt wt wt wt
8 62 non-smoker bwt het wt wt het het
9 80 49 years wt het wt wt cwt wt
10 73 27 years bwt het wt wt cwt wt
11 76 non-smoker het wt wt wt wt het
12 78 20 years het wt wt wt cwt het
Controls
1 62 non-smoker bwt het wt wt het het
2 66 non-smoker bwt het wt wt wt wt
3 73 37 years bwt het wt wt wt wt
4 79 23 years bwt wt het wt wt wt
These are compared with three SNPs associated with increased bladder cancer risk in Sak et al. (17). The 2% minor allele frequency SNP c.621 þ 22G.A was
wild-type in all 16 individuals.
ars2470352 and rs2470458 are in complete linkage.
bHeterozygote for common SNP rs2470353 C.G.
cSNP genotypes in cases 9, 10 and 12 were established by direct sequencing, as they were not included in the original 547 cases:579 control study.
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available on Carcinogenesis Online). Thirty-two controls were ran-
domly selected from our case–control series (18) and sequenced but
none of the five new variants was detected. Two variants were present
in two patients. c.621 þ 22G.A was genotyped by Taqman (95%
success rate) and found to have a minor allele frequency of 0.02 in the
control population. The OR for individuals heterozygous for the rare
allele compared with those carrying the common homozygous geno-
type was 0.9 (95% CI 0.5–1.5); therefore, this SNP was not studied
further.
The variants c.905T.C, c.156G.A, c.1177C.T and c.2251-
37.A were genotyped in germ line DNA from 771 bladder cancer
cases and 800 controls with.96% success rates. They were present in
only 0.3, 0.1, 0.9 and 0.3% of cases, respectively. No individual
carried more than one of these rare variants. When the genotypes were
combined, the OR for carriage of at least one rare allele was 3.1 (95%
CI 1.0–9.8, P 5 0.048, Table I). The genotypes of the 16 individuals
carrying one of the four rare variants were compared with our pre-
vious genotyping data for the three SNPs we previously found to be
associated with bladder cancer risk, namely rs2228000, rs2470352
and rs2470458 (17). The carriage of the rare variants was largely
associated with the rs2228000 wild-type genotype, which we previ-
ously found associated with bladder cancer risk (Table II).
Effects of the 3#UTR rare variant c.156 on transcription and mRNA
stability
GFP-expressing plasmids containing either wild-type or the 3#UTR
variant cDNA were transfected into RT112M cells, and protein ex-
pression assayed by FACS and mRNA content assayed by quantitative
real-time reverse transcription–PCR (Figure 1b). There was a signifi-
cant reduction in protein and mRNA expression in the presence of the
3#UTR variant.
Recruitment of XPC to sites of 408 nm laser-induced damage is
reduced in the presence of rare coding variants c.905T.C and
c.1177C.T
We attempted unsuccessfully to perform UV-host cell reactivation
assays in stably transfected XPC-deficient GM15983 cells. Exoge-
nous XPC protein was very unstable when expressed in XPC-de-
ficient cells using a strong SV40 promoter, consistent with
a previous report (24) and mRNA levels decreased with increasing
cellular exposure times to the selection agent Zeocin. Therefore, we
adopted a different approach. RT112M bladder cancer cells tran-
siently transfected with plasmids containing XPC cDNA fused with
GFP (Table III) were exposed to focal laser microbeam damage,
using a 408 nm (near UVA) laser microbeam (20), to generate ox-
idative damage, including DNA single and double-strand breaks
(supplementary Figure 2 is available on Carcinogenesis Online).
We specifically selected cells of intermediate fluorescence intensity
for study, and the tight error bars on these data are supportive of the
fact that such cells have similar protein expression. XPC recruitment
to the sites of damage was tracked in real time. Recruitment of the
Table III. Constructs containing XPC variants used for laser microbeam experiments and predicted changes for variants based on software tools and amino acid
chemistry
Coding variants c.905T.C
(rs121965091)
c.1177C.T
(rs121965090)
c.1496C.T
(rs2228000)
c.2059G.C
Exons Exon 7 Exon 8 Exon 8 Exon 10
Amino acid change Phe302Ser Arg393Trp Ala499Val Trp690Ser
Constructs
Wild-type XPC    
c.905T.C þ   
c.1177C.T  þ  
c.1496C.T   þ 
c.2059G.C    þ
Prediction tools
Amino acid chemistry Hydrophobic to
small polar
Positively charged
to hydrophobic aromatic
Both have similar
chemical properties
Aromatic hydrophobic
to small polar
Polyphen Probably damaging Possibly damaging Benign Probably damaging
SIFT Not tolerated Not tolerated Tolerated Not tolerated
Pfam No change No change No active domain change Active domain change
NPS@ No change in
secondary structure
No change in
secondary structure
Unclear—half of models
predict formation of Beta
sheet, half no change in
secondary structure
Possible shortening of
helical structure
Mutation nomenclature based on A of start codon ATG as nucleotide 1. Using site-directed mutagenesis, c.1399A was converted back to the wild-type C allele.
Fig. 2 Relative spot intensity versus time following 408 nm laser damage.
Plots show means and standard error of the means of 21–25 samples treated
over three independent experiments for each variant. Comparisons were
made using two-sided t-test: 499 wild-type (499 wt) and 499 mutant
(c.1496C.T), P 5 0.357, variant 302 (c.905T.C) and 499 wt, P , 0.001,
variant 393 (c.1177C.T) and 499 wt, P 5 0.004, variant 690 (c.2059G.C)
and 499 wt, P , 0.001.
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c.2059G.C mutant was low, whereas the c.499C.T variant
(rs2228000) had no effect on XPC recruitment. We found interme-
diate levels of recruitment for proteins containing the c.905T.C and
c.1177C.T variants (Figure 2).
Discussion
We have identified four new rare variants in the NER gene XPC. We
established that these were rare using a case–control study of 771
bladder cancer cases and 800 controls. A striking feature in comparing
the new rare variants with known SNP genotypes (Table II) is that
carriage of the rare variants detected in this study was largely asso-
ciated with the rs2228000 wild-type genotype, which we previously
found associated with bladder cancer risk. The combined OR in our
case–control study for the carriage of any one of these four variants
was 3.1 (95% CI 1.0–9.8, P 5 0.048) for bladder cancer risk.
There was a significant reduction in protein and mRNA expression
in the presence of the 3# UTR variant, suggestive of reduced mRNA
stability and/or transcription. Associations have been reported for 3#
UTR SNPs with alterations in mRNA stability (25–27) although cod-
ing SNPs can also have an effect via interactions with RNA-binding
proteins (28). The intrinsic stability of mRNA is determined by cis-
acting sequences located within the 3# UTR as well as trans-acting
RNA-binding proteins (25); 3# UTR variants may alter the binding
of these proteins or alter the secondary structure of the 3# UTR.
Therefore, it is feasible that the c.156 3# UTR variant has functional
effects.
The p.Trp690Ser substitution (c.2059G.C), a known XP mutation,
destabilizes XPC and causes functional defects, including severely
impaired repair of 6-4 photoproducts and lack of XPC binding to
undamaged or damaged DNA (5,29). Recruitment of the
c.2059G.C mutant was low, reflecting both its effects on protein
stability and its relative lack of binding affinity for damaged DNA.
The c.1496C.T (rs2228000) variant had no effect on XPC recruit-
ment, as was expected based on the bioinformatics analysis using the
different prediction softwares. We found intermediate levels of re-
cruitment for proteins containing the c.905T.C and c.1177C.T var-
iants (Figure 2). These variants are located within the XPA-interaction
domain (154-331) and the OGG1-interaction domain of XPC (in the
region of codon 334) (30,31) and are located in conserved regions,
suggesting that these two rare variants might alter protein–protein
interactions (supplementary Figure 3 is available on Carcinogenesis
Online).
The reductions in recruitment for c.1177C.T, c.905T.C and
c.2059G.C were in the same rank order as the severity of changes,
in terms of functional effects, domain preservation, secondary struc-
ture sequence homology and physical properties of amino acids, pre-
dicted by the software tools Polyphen, SIFT, Pfam and NPS@
(Figure 2 and Table III). Although we confirmed the low damage
recognition capability of the c.2059G.C variant (5) in our assay,
we do not yet know the underlying mechanism for reduced recruit-
ment of the c.905T.C and c.1177C.T variants. Other plasmid
assays, performed in XPC-deficient GM15983 cells, showed that
full-length XPC protein was expressed in cells transfected with the
variants c.156A, c.905T.C and c.1177C.T, respectively, although
it is not possible to comment on absolute XPC expression levels as all
were overexpressed relative to wild-type cells on western blotting
(data not shown). Further studies are needed to elucidate the specific
role of the rare variants in modulating DNA binding and DNA repair
function, as protein recruitment to focal laser damage represents only
a limited part of the DNA repair functions of XPC.
Our work on transfected mutant plasmids mimics the homozygous
mutant phenotype in humans, so the question remains as to what effect
the presence of a rare variant on only one allele might have on XPC
expression and function. Ideally, we would have wished to perform
quantitative PCR and western blot analysis of the relevant patient
samples, to determine to what extent the rare variants affect mRNA
and protein expression in the presence of a wild-type allele. Unfortu-
nately, no cell lines were made from these patients’ lymphocytes, and
ethical constraints prevent us from reapproaching these patients for
a further blood sample to help answer this question. However, Khan
et al.. (32), using quantitative reverse transcription–PCR, found re-
duced XPC mRNA levels (59% of normal controls) and reduced
XPC protein levels in cells from clinically normal parents of XP-C
patients, where the patients’ cells had premature termination codons,
nonsense-mediated mRNA decay and absence of full length or trun-
cated XPC protein on western blotting. They proposed that a half dose
of the XPC gene product may be insufficient for full XPC function in
the maintenance of genomic integrity, thus, giving rise to an increased
mutation rate. In support of this, germ line XP heterozygosity has
been identified as a risk factor for lung cancer (33), including
Arg671Cys in XPC which is predicted to be probably damaging by
SIFT and Polyphen. Also, Xpcþ/ mice develop skin tumours after
daily UVB exposure although at an older age than Xp-/ mice. The
great majority of skin tumours are mutated in one or both Trp53
alleles, suggesting that p53 function may influence the increased can-
cer risk. In support of this, Xpa//Trp53þ/ mice are even more
prone to bladder tumour formation than Trp53þ/ mice following 2-
acetylaminofluorene exposure, whereas Xpa/ mice do not develop
bladder tumours (34).
It is currently uncertain what relative contribution common and rare
genetic variants make to cancer predisposition. The ‘common disease-
multiple rare variants’ hypothesis proposes that ‘a significant propor-
tion of the inherited susceptibility to cancer may be due to the
summation of the effects of a series of low frequency dominantly
and independently acting variants of a variety of different genes, each
conferring a moderate but readily detectible increase in the relative
risk’ (35). Fearnhead et al. (36), in 124 multiple colorectal adenoma
patients and 483 controls, found 24.9% of cases but only 11.5% of
controls carried potentially pathogenic variants in five candidate
genes implicated in colorectal tumorigenesis. It is also possible that
rare variants function as compound heterozygotes, with a different
rare variant present on each allele. In colorectal cancer, Tenesa
et al. (37), found a strong bilallelic effect for two MUTYH rare var-
iants, coding for Tyr165Cys (c.494A.G and rs34612342) and
Gly382Asp (c.1145G.A and rs36053993), which included com-
pound heterozygotes (relative risk 117 (95% CI 74–184) compared
with the small but significant mono-allelic effect [genotype relative
risk 1.27 (95% CI 1.01–1.61)].
In an appraisal of XPD polymorphisms and DNA repair capacity
and cancer susceptibility, Clarkson et al. (38) argued against under-
taking genotyping studies for variants where their functional effect is
yet to be established. Rather, they suggested a combination of several
approaches, including use of analytical algorithms, host cell reactiva-
tion assays in an isogenic background and estimation of protein ex-
pression levels. The study of rare variants also requires a similar
approach, and Bodmer et al. (35) propose that candidate genes should
be selected which are known to be involved in the biology of the
disease, and where severe disruption of function gives rise to a severe
version of the disease. These genes then need to be sequenced in
patients with the disease to identify rare variants, which are assessed
for their potential consequences based on prediction software and on
biochemical and physiological studies, and subsequently assessed for
their frequency in an appropriate control population. We are largely
following such an approach, using XPC as a candidate gene. However,
severe disruption of XPC function has not been associated with blad-
der cancer in XP-C patients, although these patients die at a young age
of their skin tumours, and to our knowledge, bladder tumours have not
been reported in XPC knockout mice. However, XPC knockout mice
develop more bladder tumours than wild-type mice after exposure to
2-acetylaminofluorene, a metabolite of which forms bulky DNA ad-
ducts (39). It is thus probable that in bladder cancer rare XPC variants
act by influencing environmental or occupational exposures, as mech-
anistic studies have shown that bulky DNA adducts formed by aro-
matic amines are repaired by NER, in epidemiological studies these
are associated with increased bladder cancer risk, and case–control
studies have demonstrated increased bladder cancer risk in the pres-
ence of XPC SNPs.
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The high cost of mutation scanning techniques and conventional
‘Sanger’ sequencing has limited systematic searches for rare variants
(40), but the recent emergence of clonal sequencing technology
(41,42) makes such work more cost effective. Now that it is possible
to examine large numbers of DNA samples for rare variants, it will be
important to use prediction software tools combined with functional
assays to determine which variants are worthwhile to study further. In
this present study, we have validated two relatively straightforward
assays that could be used: firstly, the recruitment of GFP-tagged XPC
proteins to 408 nm laser damage, an assay which is appropriate for the
evaluation of a range of DNA repair genes, and secondly, the 3# UTR
assay which is generic and so could be applied to any gene.
Supplementary material
Supplementary Tables I–III and Figures 1–3 can be found at http://
carcin.oxfordjournals.org/
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